RxDoctor Payments Data

Raman Michael, MD

Ophthalmology · Arlington Heights, ILNPI 1346701950

Payments from drug & device makers

$2,006in general payments, 2019–2025

Across 50 payments — averaging $40.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • AbbVie$462
  • Sight Sciences, Inc.$142
  • Glaukos Corporation$62
  • Thea Pharma Inc.$48
  • NEW World Medical,inc.$34
  • plus $77 from 4 others

What the payments were for

  • Travel & lodging$79740%
  • Food & beverage$1,20960%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,006 in reported general payments places this provider in the 55th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$48,376
Medicare patients
138
Services billed
563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate96$48,272
LumiganBimatoprost61$29,575
CombiganBrimonidine Tartrate/Timolol57$22,074
Alphagan PBrimonidine Tartrate46$15,412
Prednisolone Acetate212$9,960
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol52$8,747
SimbrinzaBrinzolamide/Brimonidine Tart38$8,097
Latanoprost574$7,003
Brimonidine Tartrate213$6,953
Travoprost46$6,745
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat404$6,565
RocklatanNetarsudil Mesylat/Latanoprost14$6,027
Brinzolamide45$5,234
Dorzolamide Hcl214$4,500
Ofloxacin166$2,912

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$462$67,061164 claims
AlconSimbrinza$1,182$8,09738 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Arlington Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →